PHAXIAM Therapeutics develops antibacterial treatments based on the use of bacteriophage viruses to combat bacterial infections, particularly those resistant to antibiotics. The company addresses antimicrobial resistance, which is a major global health issue.

PHAXIAM Therapeutics

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

ERYTECH Pharma S.A.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 3:18 AM	1ac12589
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 3:18 AM	f6b40ca2
crunchbase trigger	general	Nov 18, 2024 2:12 PM	618f42df
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Oct 16, 2024 3:18 AM	3bb43262
news basic	general	Oct 16, 2024 3:18 AM	0e13bebd
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ERYTECH

PHAXIAM Therapeutics

Last Close

0.80

28/06 15:35

Market Cap

48.66M

Beta: -

Volume Today

27.49K

Avg: -